Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Andrew M Slee"'
Autor:
Trudy H. Grossman, Corey Fyfe, William O’Brien, Meredith Hackel, Mary Beth Minyard, Ken B. Waites, Jacques Dubois, Timothy M. Murphy, Andrew M. Slee, William J. Weiss, Joyce A. Sutcliffe
Publikováno v:
mSphere, Vol 2, Iss 1 (2017)
ABSTRACT TP-271 is a novel, fully synthetic fluorocycline antibiotic in clinical development for the treatment of respiratory infections caused by susceptible and multidrug-resistant pathogens. TP-271 was active in MIC assays against key community re
Externí odkaz:
https://doaj.org/article/fc839a5a5190439892aac4f57b1d746e
Autor:
Kevin M. Krause, Wright W. Nichols, Peter J. Laud, Eric Gangl, Petar Pop-Damkov, Taryn Sleger, Andrew M Slee
Publikováno v:
Journal of Chemotherapy. 30:95-100
Efficacies of ceftazidime-avibactam (4:1 w/w) and ceftazidime were tested against ceftazidime-susceptible (blaKPC-2-negative), and meropenem- and ceftazidime-resistant (blaKPC-2-positive), Klebsiella pneumoniae in a 52-h, multiple dose, abdominal abs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d38c3bec2cda44dd6091c8698afcb3c7
https://doi.org/10.1080/1120009x.2017.1405609
https://doi.org/10.1080/1120009x.2017.1405609
Autor:
Taryn, Sleger, Eric, Gangl, Petar, Pop-Damkov, Kevin M, Krause, Peter J, Laud, Andrew M, Slee, Wright W, Nichols
Publikováno v:
Journal of chemotherapy (Florence, Italy). 30(2)
Efficacies of ceftazidime-avibactam (4:1 w/w) and ceftazidime were tested against ceftazidime-susceptible (bla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c4a4765a1da47d10d6961ff6e2f12b28
https://pubmed.ncbi.nlm.nih.gov/29191131
https://pubmed.ncbi.nlm.nih.gov/29191131
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:2567-2571
Eravacycline is a novel broad-spectrum fluorocycline antibiotic being developed for a wide range of serious infections. Eravacycline was efficacious in mouse septicemia models, demonstrating 50% protective dose (PD 50 ) values of ≤1 mg/kg of body w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb75bd424cc3ff2e2c21a8642402c2e0
https://doi.org/10.1128/aac.04354-14
https://doi.org/10.1128/aac.04354-14
Autor:
Mariana Castells, Cem Akin, Susan V. Jennings, Jan B. Hempstead, Andrew M. Slee, Angela S. Bowman, Valerie M. Slee
Publikováno v:
Journal of Allergy and Clinical Immunology. 143:AB427
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d28957ecb52118012202c04f272f2a5
https://doi.org/10.1016/j.jaci.2018.12.962
https://doi.org/10.1016/j.jaci.2018.12.962
Publikováno v:
Expert Opinion on Investigational Drugs. 11:1765-1774
Integrins are involved in many cellular processes, including some pathological ones associated with various cancers, both solid tumours and metastases. Since integrins are involved in such critical processes as gene expression, which lead to cellular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::768ef9b5c1e61844327328ce5d4e9845
https://doi.org/10.1517/13543784.11.12.1765
https://doi.org/10.1517/13543784.11.12.1765
Autor:
George L. Trainor, Andrew P. Combs, Karen Amsler, Dong Liang Zhan, Andrew M. Stern, Robert A. Copeland, Tasir Shamsul Haque, Christine F. Sizemore, Lisa D. Ecret, Lisa M. Kopcho, Seifu Tadesse, Andrew M. Slee, Frank W. Hobbs, M. John Rogers, Jovita Marcinkeviciene
Publikováno v:
Journal of Medicinal Chemistry. 45:4669-4678
The identification of several potent pyrazole-based inhibitors of bacterial dihydroorotate dehydrogenase (DHODase) via a directed parallel synthetic approach is described below. The initial pyrazole-containing lead compounds were optimized for potenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::039f4c4515594fb0da094487fc62ca17
https://doi.org/10.1021/jm020112w
https://doi.org/10.1021/jm020112w
Autor:
Jayson J. Merrill, Lorie A. Foster, D. Andrew Stevenson, Andrew M. Slee, Karen M. Amsler, Christine F. Sizemore, Todd C. Modzelewski, Joel D. Quispe
Publikováno v:
Antimicrobial Agents and Chemotherapy. 46:1435-1440
We evaluated the effect of optimized doses and dosing schedules of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline (BMT) triple therapy with only 1 day of dosing on Helicobacter pylori SS1 titers in a mouse model. A reduction of b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::008681d3215f66d1dc8554e05fedc750
https://doi.org/10.1128/aac.46.5.1435-1440.2002
https://doi.org/10.1128/aac.46.5.1435-1440.2002
Autor:
Yong P. Yan, Andrew M. Slee, Utpal Patel, Michael G. Kurilla, David L. Pompliano, Frank W. Hobbs, Janet Kaczmarczyk, Ekaterina V. Bobkova
Publikováno v:
Journal of Biological Chemistry. 276:37199-37205
Oxazolidinones are potent inhibitors of bacterial protein biosynthesis. Previous studies have demonstrated that this new class of antimicrobial agent blocks translation by inhibiting initiation complex formation, while post-initiation translation by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66abebebcfcee42de1cbc5537c1705b4
https://doi.org/10.1074/jbc.m102966200
https://doi.org/10.1074/jbc.m102966200
Publikováno v:
British Journal of Pharmacology. 133:331-336
A number of non-peptide orally active RGD mimetic prodrug such as Orbofiban, Sibrafiban, SR121566, Roxifiban and others entered into the clinical evaluation stage. Some of these agents were terminated and some are still in clinical trials. The presen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::586dd6b0f5b8ae34a9f439c0d0255486
https://doi.org/10.1038/sj.bjp.0703943
https://doi.org/10.1038/sj.bjp.0703943